Clariant AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLZNY research report →
Price Chart
About the company
Clariant AG operates as a global leader in specialty chemicals, organized into three primary business units: Care Chemicals, Catalysis, and Natural Resources. The company develops and supplies a broad spectrum of chemical products and solutions. This includes fire retardants, performance-enhancing additives, and advanced surface treatments for applications spanning plastics, coatings, inks, and consumer goods.
- CEO
- Conrad Keijzer
- IPO
- 2009
- Employees
- 10,281
- HQ
- Muttenz, BL, CH
Get TickerSpark's AI analysis on CLZNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.23B
- P/E
- -107.50
- Fwd P/E
- 19.82
- PEG
- -1.07
- P/S
- 0.93
- P/B
- 1.75
- EV/EBITDA
- 8.42
- Div Yield
- 3.91%
- Gross Margin
- 30.99%
- Op Margin
- 9.93%
- Net Margin
- -0.81%
- ROE
- -1.52%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $3.74B-9.9%
- Gross Profit
- $1.17B-7.4%
- Op Income
- $380.11M
- Net Income
- $-71,628,218-129.4%
- EPS
- $-0.22-129.7%
- OCF Growth
- -13.4%
- FCF Growth
- +6.9%
- 52W High
- $13.96
- 52W Low
- $8.50
- 50D MA
- $12.76
- 200D MA
- $11.14
- Beta
- 0.41
- RSI (14)
- 51
- Avg Volume
- 160
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Clariant posted solid Q3 local-currency sales growth and guided to an unchanged full-year 2026 outlook, with Q4 expected to be stronger on Catalysts mix and continued momentum in Care Chemicals and Additives.· November 3, 2026
- Q3 sales were CHF 968 million, up 5.6% in local currency; excluding portfolio pruning, sales rose 6.7%.
- EBITDA before exceptional items fell 6.5% to CHF 151.5 million, with margin down to 15.6% from 17.9% a year ago.
- Care Chemicals grew strongly, but margin slipped to 17.5% from 19.0% because of mix and inventory/raw-material effects.
- Catalysts remained the weak spot: sales rose 1.8% in local currency, but EBITDA dropped 29.4% to CHF 23.1 million as Middle East disruption delayed high-margin orders.
- Management left 2026 guidance unchanged: sales around 2025 levels in local currency, EBITDA margin around 18%, and free cash flow conversion above 45%.
Clariant reported Q3 sales of CHF 968 million, up 5.6% in local currency, or up 6.7% excluding portfolio pruning; reported sales also benefited from a 1.3% currency tailwind. EBITDA before exceptional items was CHF 151.5 million, down 6.5% year over year, and the margin was 15.6% versus 17.9% last year. By segment, Care Chemicals EBITDA was CHF 93 million with a 17.5% margin, Catalysts EBITDA was CHF 23.1 million with a 13.3% margin, and Adsorbents & Additives EBITDA was CHF 48.9 million with an 18.5% margin. For the full year 2026, management reiterated guidance for sales around 2025 levels in local currency, an EBITDA margin of around 18% before exceptional items, and free cash flow conversion of over 45%.
Conrad Keijzer said the quarter showed strong underlying sales momentum despite a volatile environment, with positive pricing across all three business units and continued pressure from the Middle East conflict on Catalysts and oil services. He emphasized that Q4 should be stronger, pointing to a solid order book, especially in Catalysts, and favorable mix. His tone was constructive but cautious, repeatedly framing the outlook around geopolitical uncertainty and active pricing/cost management.
Oliver Rittgen highlighted the quarter’s margin pressure from mix and non-recurring effects, noting that Q3 EBITDA margin was hit by inventory valuation, raw-material volatility, and a stronger contribution from lower-margin industrial business within Care Chemicals. He also detailed the cost environment, saying pricing largely offset 12% higher raw materials, 9% higher energy, and 24% higher logistics costs. On capital allocation, he said CapEx is expected at the lower end of the CHF 150 million to CHF 175 million range, and that the company remains disciplined on working capital, CapEx, and investment-grade balance-sheet priorities. He also pointed to performance improvement programs with CHF 79 million of cumulative run-rate savings achieved, versus CHF 90 million expected by end-2026 and CHF 100 million by 2027.
Analysts focused heavily on the credibility of the Q4 ramp and the path to the full-year 18% EBITDA margin. Management said October started well across all businesses, that Catalysts has a stronger order book and better mix, and that year-to-date EBITDA margin is 17.1%, so Q4 should lift the full-year outcome. Questions also pressed on M&A rumors and the rumored Ashland interest; management declined to comment on rumors and reiterated that any deal would need to be bolt-on, strategically relevant, and consistent with an investment-grade rating. On litigation, management said there was no new news on the Shell case beyond the appeal being filed and stressed that the July Amsterdam District Court decision was overwhelmingly favorable to Clariant.
The call showed that Clariant is still growing in local currency despite a tough market, with Care Chemicals and Adsorbents & Additives both posting solid momentum and positive pricing. Management also sounded confident on Q4, citing a strong Catalysts order book, better mix, improving force-majeure conditions outside the Middle East, and ongoing savings from performance programs.
Margins fell sharply in Q3, especially in Catalysts, where Middle East disruption, delayed high-margin orders, and inventory valuation hurt profitability. The company continues to face geopolitical uncertainty, elevated input and logistics costs, and weak industry conditions, with management noting that the global chemical market outlook for 2026 has worsened to negative 0.6% growth. There is also ongoing litigation risk from the Shell appeal, even though management remains confident in the district court ruling.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 59.3%
- Shares Outstanding
- 328.88M
- Float Shares
- 195.07M
of shares held by institutions
1 13F filers
Our CLZNY coverage
Recent articles, reports, and earnings notes.
No research on CLZNY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLZNY report →Clariant AG (CLZNY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Clariant lags core profit forecast as Iran war weighs, but says the hit is easing
reuters.com · Nov 3
Clariant AG (OTCMKTS:CLZNY) Receives Average Recommendation of “Hold” from Analysts
defenseworld.net · Aug 17
Clariant AG (CLZNY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 31
Clariant AG (CLZNY) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 8
Clariant delivers resilient performance in challenging environment
globenewswire.com · May 8
Clariant publishes Integrated Report 2025
globenewswire.com · Feb 27
Clariant AG (CLZNY) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.